HDAC8 Activates AKT through Upregulating PLCB1 and Suppressing DESC1 Expression in MEK1/2 Inhibition-Resistant Cells

Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity

(2020) Shannon Lee et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Multi-omic profiling reveals associations between the gut mucosal microbiome, the metabolome, and host DNA methylation associated gene expression in patients with colorectal cancer

(2020) Qing Wang et al.   BMC MICROBIOLOGY

Targeting GSK3 and Associated Signaling Pathways Involved in Cancer

(2020) Przemysław Duda et al.   Cells

Exportin-5 SUMOylation promotes hepatocellular carcinoma progression

(2020) Dongdong Lin et al.   EXPERIMENTAL CELL RESEARCH

Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review

(2020) Ilaria Proietti et al.   Cancers

AKT as a Therapeutic Target for Cancer

(2019) Mengqiu Song et al.   CANCER RESEARCH

HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy

(2019) Michael F. Emmons et al.   CANCER RESEARCH

Distinct Prognostic Values of Phospholipase C Beta Family Members for Non-Small Cell Lung Carcinoma

(2019) Tengfang Zhang et al.   Biomed Research International

CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition

(2019) Amir Noeparast et al.   ONCOGENE

LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1

(2018) Zhi-wei Chang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Targeted inhibition of HDAC8 increases the doxorubicin sensitivity of neuroblastoma cells via up regulation of miR-137

(2017) Gang Zhao et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

HDAC8 Prevents Anthrax Lethal Toxin-induced Cell Cycle Arrest through Silencing PTEN in Human Monocytic THP-1 Cells

(2017) et al.   Toxins

DESC1, a novel tumor suppressor, sensitizes cells to apoptosis by downregulating the EGFR/AKT pathway in esophageal squamous cell carcinoma

(2016) Hoi Yan Ng et al.   INTERNATIONAL JOURNAL OF CANCER

PI-PLCβ1b affects Akt activation, cyclin E expression, and caspase cleavage, promoting cell survival in pro-B-lymphoblastic cells exposed to oxidative stress

(2015) Manuela Piazzi et al.   FASEB JOURNAL

Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models

(2015) Stefanie Schrauwen et al.   GYNECOLOGIC ONCOLOGY

The kinase Jnk2 promotes stress-induced mitophagy by targeting the small mitochondrial form of the tumor suppressor ARF for degradation

(2015) Qiao Zhang et al.   NATURE IMMUNOLOGY

HDAC8: a multifaceted target for therapeutic interventions

(2015) Alokta Chakrabarti et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Phosphorylation of AKT: a Mutational Analysis.

(2015) Jonathan R. Hart et al.   Oncotarget

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance

(2015) James Andrew McCubrey et al.   Oncotarget

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies

(2014) C. M. Lovly et al.   CLINICAL CANCER RESEARCH

HDAC8-Mediated Epigenetic Reprogramming Plays a Key Role in Resistance to Anthrax Lethal Toxin-Induced Pyroptosis in Macrophages

(2014) S.-D. Ha et al.   JOURNAL OF IMMUNOLOGY

Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities

(2014) Diane E. Peters et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF -Mutated Melanoma

(2014) Marian M. Deuker et al.   Cancer Discovery

K562 cell proliferation is modulated by PLCβ1 through a PKCα-mediated pathway

(2013) Alessandro Poli et al.   CELL CYCLE

Phosphoinositide-specific Phospholipase C β 1b (PI-PLCβ1b) Interactome: Affinity Purification-Mass Spectrometry Analysis of PI-PLCβ1b with Nuclear Protein

(2013) Manuela Piazzi et al.   MOLECULAR & CELLULAR PROTEOMICS

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

(2013) Cory M. Johannessen et al.   NATURE

TEM8/ANTXR1 Blockade Inhibits Pathological Angiogenesis and Potentiates Tumoricidal Responses against Multiple Cancer Types

(2012) Amit Chaudhary et al.   CANCER CELL

BRAF mutations in melanoma and colorectal cancer: A single oncogenic mutation with different tumour phenotypes and clinical implications

(2012) F. Sclafani et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

(2012) Libero Santarpia et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

(2012) Ryan B. Corcoran et al.   Cancer Discovery

BRAF L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

(2012) Kimberly Brown Dahlman et al.   Cancer Discovery

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Phosphoinositide Phospholipase Cβ1 (PI-PLCβ1) Gene in Myelodysplastic Syndromes and Cytogenetically Normal Acute Myeloid Leukemia: Not a Deletion, but Increased PI-PLCβ1 Expression Is an Independent Prognostic Factor

(2010) Frederik Damm et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of some human genes oppositely regulated during esophageal squamous cell carcinoma formation and human embryonic esophagus development

(2009) M. V. Zinovyeva et al.   DISEASES OF THE ESOPHAGUS

Involvement of nuclear PLCβ1 in lamin B1 phosphorylation and G2/M cell cycle progression

(2008) Roberta Fiume et al.   FASEB JOURNAL